Dupont Capital Management Corp increased its holdings in shares of FibroGen Inc (NASDAQ:FGEN) by 108.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,860 shares of the biopharmaceutical company’s stock after buying an additional 8,253 shares during the period. Dupont Capital Management Corp’s holdings in FibroGen were worth $734,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in FGEN. FMR LLC increased its stake in FibroGen by 22.9% during the 2nd quarter. FMR LLC now owns 8,404,819 shares of the biopharmaceutical company’s stock worth $526,142,000 after buying an additional 1,566,040 shares during the period. First Trust Advisors LP increased its stake in FibroGen by 37.8% during the 3rd quarter. First Trust Advisors LP now owns 1,652,213 shares of the biopharmaceutical company’s stock worth $100,372,000 after buying an additional 453,288 shares during the period. Candriam Luxembourg S.C.A. increased its stake in FibroGen by 118.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 410,900 shares of the biopharmaceutical company’s stock worth $24,962,000 after buying an additional 222,800 shares during the period. Handelsbanken Fonder AB increased its stake in FibroGen by 82.8% during the 4th quarter. Handelsbanken Fonder AB now owns 347,400 shares of the biopharmaceutical company’s stock worth $16,078,000 after buying an additional 157,400 shares during the period. Finally, Man Group plc grew its holdings in FibroGen by 151.5% during the 3rd quarter. Man Group plc now owns 256,853 shares of the biopharmaceutical company’s stock worth $15,603,000 after acquiring an additional 154,719 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO Thomas B. Neff sold 48,180 shares of the company’s stock in a transaction on Friday, February 8th. The shares were sold at an average price of $56.47, for a total value of $2,720,724.60. Following the completion of the transaction, the chief executive officer now owns 2,680,346 shares in the company, valued at approximately $151,359,138.62. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider K Peony Yu sold 3,422 shares of the company’s stock in a transaction on Friday, December 14th. The shares were sold at an average price of $38.58, for a total transaction of $132,020.76. Following the completion of the transaction, the insider now owns 144,123 shares of the company’s stock, valued at approximately $5,560,265.34. The disclosure for this sale can be found here. Insiders have sold a total of 249,568 shares of company stock valued at $11,808,518 in the last quarter. 8.96% of the stock is currently owned by company insiders.
NASDAQ FGEN opened at $57.56 on Thursday. The company has a quick ratio of 6.76, a current ratio of 6.76 and a debt-to-equity ratio of 0.20. FibroGen Inc has a 52 week low of $37.27 and a 52 week high of $68.55. The company has a market cap of $4.94 billion, a price-to-earnings ratio of -33.27 and a beta of 1.77.
FGEN has been the subject of several analyst reports. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a report on Wednesday, October 17th. BidaskClub cut shares of FibroGen from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. TheStreet cut shares of FibroGen from a “c-” rating to a “d+” rating in a report on Wednesday, November 21st. Mizuho reiterated a “buy” rating and set a $74.00 price target on shares of FibroGen in a report on Monday, December 17th. Finally, Citigroup upgraded shares of FibroGen from a “neutral” rating to a “buy” rating and set a $71.00 price target for the company in a report on Tuesday, December 18th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $70.40.
COPYRIGHT VIOLATION WARNING: “Dupont Capital Management Corp Acquires 8,253 Shares of FibroGen Inc (FGEN)” was originally published by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://macondaily.com/2019/02/14/dupont-capital-management-corp-acquires-8253-shares-of-fibrogen-inc-fgen.html.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Further Reading: What is a Leveraged Buyout (LBO)?
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.